CorMedix (CRMD)
(Real Time Quote from BATS)
$7.73 USD
+0.22 (2.93%)
Updated Sep 25, 2024 01:00 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
CorMedix Inc [CRMD]
Reports for Purchase
Showing records 41 - 60 ( 101 total )
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
1Q 2018 Financial Results Reported; Timelines Revised; Reducing Price Target to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Neutrolin Phase 3 Interim Analysis Approaches; Near- Term Runway Appears Adequate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
LOCK-IT-100 Trial Reaches Interim Analysis Event Accrual Milestone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
SMALL-CAP SQUAWK
Provider: JGR Capital Partners
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Expert Discussion Emphasizes Infection Severity in Long-Term Catheterization; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Doing the Bacterial Bossa Nova: The Next Wave of Antibiotic Therapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Recent Management Discussions Highlight Medical Device Pipeline; Raising Price Target to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2Q17 Results Reported; Interim Analysis Approaching; Reiterate Buy and Reducing Price Target
Provider: Rodman & Renshaw, Co.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2Q17 Results Reported; Interim Analysis Approaching; Reiterate Buy and Reducing Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
1Q17 Financial Results Reported; Neutrolin? Interim Analysis Approaching; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
1Q17 Financial Results Reported; Neutrolin - Interim Analysis Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2016 Financial Results; Financing Completed; Adjusting Price Target to $5.00
Provider: Rodman & Renshaw, Co.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2016 Financial Results; Financing Completed; Adjusting Price Target to $5.00
Provider: H.C. Wainwright & Co., Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
3Q16 Results Reported; Neutrolin Phase 3 Enrollment Challenges; Reducing Price Target
Provider: Rodman & Renshaw, Co.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
3Q16 Results Reported; Neutrolin Phase 3 Enrollment Challenges; Reducing Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
We are dropping coverage to reallocate our research resources
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2Q16 Results Reported: Neutrolin Trial Progress Continues; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2Q16 Results Reported: Neutrolin Trial Progress Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Phase 3 Program Progress; 1Q 2016 Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.